Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
DOI
PMC
 |
Open Access Gold |
|
as soon as is submitted to ZB.
The nuclear speckles protein SRRM2 is exposed on the surface of cancer cells.
Cells 13:1563 (2024)
The membrane composition of extracellular vesicles (EVs) largely reflects that of the plasma membrane of the cell of origin. We therefore hypothesized that EVs could be used for immunizations to generate monoclonal antibodies against well-known tumor antigens but possibly also against hitherto unknown tumor-associated target molecules. From an immunization experiment, we obtained a monoclonal antibody specific for SRRM2, an RNA-binding protein involved in splicing and a major component of nuclear speckles. Here, we used this antibody to demonstrate that SRRM2 is exposed on the surface of most cancer cell lines from various entities and, even more important, on cancer cells in vivo. Moreover, we demonstrated that SRRM2-specific CAR-T cells are functional in vitro and in vivo. Collectively, we identified SRRM2 as a promising new target molecule exposed on the cancer cell surface and showed that our SRRM2-specific antibody can be used as a basis for the development of new targeted cancer therapies.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Srrm2 ; Cancer Target ; Target Identification ; Therapeutic Antibodies; Srm160/300 Splicing Coactivator; Sr Proteins; Label-free; Exosomes; Target
ISSN (print) / ISBN
2073-4409
e-ISSN
2073-4409
Journal
Cells
Quellenangaben
Volume: 13,
Issue: 18,
Article Number: 1563
Publisher
MDPI
Publishing Place
Basel
Non-patent literature
Publications
Institute(s)
Institute of Structural Biology (STB)
CF Monoclonal Antibodies (CF-MAB)
CF Metabolomics & Proteomics (CF-MPC)
CF Monoclonal Antibodies (CF-MAB)
CF Metabolomics & Proteomics (CF-MPC)